A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function

Inclusion Criteria: * Voluntarily participate in the clinical study and sign the written ICF, be able to understand the procedures and methods of this study, and be able to complete the entire study process according to the study requirements; * Age 18 to 70 years (inclusive) on the day of signing the ICF, male or female; * Body weight: ≥ 50 kg for males, ≥ 45 kg for females; body mass index (BMI): 18.0-32.0 kg/m2 (both inclusive); * Subjects (including their partners) have no birth plan from screening until 3 months after the administration of the investigational product and voluntarily take contraceptive measures, and have no plans to donate sperm or eggs; * Glomerular filtration rate (calculated using the CKD-EPI formula) ≥ 60 mL/min; Exclusion Criteria: * Known or suspected history of immunodeficiency (e.g., history of frequent recurrent infections), hereditary or acquired complement deficiency; * Clear history of capsular microbial infection within 6 months before screening, including but not limited to Streptococcus pneumoniae, Bacillus anthracis, Salmonella, Salmonella typhi, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, Neisseria meningitidis, Haemophilus influenzae and Legionella pneumophila. * Subjects who have a previous history of tuberculosis infection or are currently suffering from tuberculosis infection; * Active systemic bacterial, viral or fungal infections within 14 days before administration; * Fever (≥ 38°C) within 7 days before …